DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Zyflo CR (Zileuton) - Side Effects and Adverse Reactions

 
 



ADVERSE REACTIONS

Hepatotoxicity: Elevations of one or more hepatic function enzymes and bilirubin may occur during ZYFLO CR therapy [see Warnings and Precautions (5) ].

The most commonly occurring adverse reactions (≥5%) with ZYFLO CR are sinusitis, nausea, and pharyngolaryngeal pain.

Short-Term Clinical Studies Experience

The safety data described below reflect exposure to ZYFLO CR in 199 patients for 12 weeks duration. In a 12-week, randomized, double-blind, placebo-controlled trial in adults and adolescents 12 years of age and older with asthma, patients received ZYFLO CR two 600 mg tablets (n=199) or placebo (n=198) twice daily by mouth. Eighty-three percent of patients were white, 48% were male, and the mean age was 34 years.

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

The most commonly reported adverse reactions (occurring at a frequency of ≥5%) in ZYFLO CR-treated patients and at a frequency greater than placebo-treated patients are reflected in Table 1.

Table 1 Adverse Reactions with ≥5% Incidence in a 12-Week Placebo-Controlled Trial in Patients with Asthma
Adverse ReactionZYFLO CR
600 mg
2 Tablets
Twice Daily
N=199
n (%)
Placebo
2 Tablets
Twice Daily
N=198
n (%)
  Sinusitis13 (6.5)8 (4.0)
  Nausea10 (5.0)3 (1.5)
  Pharyngolaryngeal pain10 (5.0)8 (4.0)

Less common adverse reactions occurring at a frequency ≥1% and more often in the ZYFLO CR group than in the placebo group included gastrointestinal disorders (upper abdominal pain, diarrhea, dyspepsia, vomiting), rash, hypersensitivity, and hepatotoxicity.

There were no differences in the incidence of adverse reactions based upon gender. The clinical trials did not include sufficient numbers of patients <18 years of age or non-Caucasians to determine whether there is any difference in adverse reactions based upon age or race.

Hepatotoxicity

In the 12-week placebo-controlled trial, the incidence of ALT elevations (≥3×ULN) was 2.5% (5 of 199) in the ZYFLO CR group, compared to 0.5% (1 of 198) in the placebo group. In the ZYFLO CR group, the majority of ALT elevations (60%) occurred in the first month of treatment, and in 2 of the 5 patients in the ZYFLO CR group, ALT elevations were detected 14 days after completion of the 3-month study treatment. The levels returned to <2×ULN or normal within 9 and 12 days, respectively. The ALT elevations in the other 3 patients were observed to return to <2×ULN or normal within 15, 19, and 31 days after ZYFLO CR discontinuation. There appeared to be no clinically relevant relationship between the time of onset and the magnitude of the first elevation or the magnitude of first elevation and time to resolution. The hepatic function enzyme elevations attributed to ZYFLO CR did not result in any cases of jaundice, development of chronic liver disease, or death in this clinical trial.

Long-Term Clinical Studies Experience

The safety of ZYFLO CR was evaluated in one 6-month, randomized, double-blind, placebo-controlled clinical trial in adults and adolescents 12 years of age and older with asthma. Patients received two 600 mg ZYFLO CR tablets (n=619) or placebo (n=307) twice daily by mouth along with usual asthma care. Eighty-six percent of patients were white, 40% were male, and the overall mean age was 36.

The rate and type of adverse reactions observed in this study were comparable to the adverse reactions observed in the 12-week study. Other commonly reported adverse reactions (occurring at a frequency of ≥5%) in ZYFLO CR-treated patients and at a frequency greater than placebo-treated patients included the following: headache (23%), upper respiratory tract infection (9%), myalgia (7%), and diarrhea (5%) compared to 21%, 7%, 5% and 2%, respectively, in the placebo-treated group.

ALT elevations (≥3×ULN) were observed in 1.8% of patients treated with ZYFLO CR compared to 0.7% in patients treated with placebo. The majority of elevations (82%) were reported within the first 3 months of treatment and resolved within 21 days for most of these patients after discontinuation of the drug. The hepatic function enzyme elevations attributed to ZYFLO CR did not result in any cases of jaundice, development of chronic liver disease, or death in this clinical trial.

Occurrences of low white blood cell (WBC) count (<3.0 × 109/L) were observed in 2.6% (15 of 619) of the ZYFLO CR-treated patients and in 1.7% (5 of 307) of the placebo-treated patients. The WBC counts returned to normal or baseline following discontinuation of ZYFLO CR. The clinical significance of these findings is not known.

Postmarketing Experience

The following adverse reactions have been identified during post-approval use of zileuton immediate-release tablets and may be applicable to ZYFLO CR. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship.

Cases of severe hepatic injury have been reported in patients taking zileuton immediate-release tablets. These cases included death, life-threatening liver injury with recovery, symptomatic jaundice, hyperbilirubinemia, and elevations of ALT >8×ULN.



REPORTS OF SUSPECTED ZYFLO CR SIDE EFFECTS / ADVERSE REACTIONS

Below is a sample of reports where side effects / adverse reactions may be related to Zyflo CR. The information is not vetted and should not be considered as verified clinical evidence.

Possible Zyflo CR side effects / adverse reactions in 54 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2011-11-10

Patient: 54 year old female weighing 86.2 kg (189.6 pounds)

Reactions: Product Formulation Issue, Mood Altered, Arthralgia, Decreased Activity, Treatment Failure, Exercise Tolerance Decreased

Suspect drug(s):
Zyflo CR
    Dosage: 2 tabs
    Administration route: Oral
    Indication: Bronchial Hyperreactivity

Zyflo CR
    Dosage: 2 tabs
    Administration route: Oral
    Indication: Asthma



Possible Zyflo CR side effects / adverse reactions in 36 year old male

Reported by a consumer/non-health professional from United States on 2012-08-01

Patient: 36 year old male

Reactions: Death

Adverse event resulted in: death

Suspect drug(s):
Zyflo CR

Other drugs received by patient: Advair; Zolair



See index of all Zyflo CR side effect reports >>

Drug label data at the top of this Page last updated: 2007-08-03

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017